Literature DB >> 16223879

Friend spleen focus-forming virus transforms rodent fibroblasts in cooperation with a short form of the receptor tyrosine kinase Stk.

Kazuo Nishigaki1, Charlotte Hanson, Tanya Jelacic, Delores Thompson, Sandra Ruscetti.   

Abstract

Friend spleen focus-forming virus (SFFV) causes rapid erythroleukemia in mice due to expression of its unique envelope glycoprotein, gp55. Erythroid cells expressing SFFV gp55 proliferate in the absence of their normal regulator erythropoietin (Epo) because of constitutive activation of Epo signal transduction pathways. Although SFFV infects many cell types, deregulation of cell growth occurs only when SFFV infects erythroid cells, suggesting that these cells express unique proteins that the virus requires to mediate its biological effects. Not only do erythroid cells express the Epo receptor (EpoR), but those from mice susceptible to SFFV-induced erythroleukemia also express a short form of the receptor tyrosine kinase Stk (sf-Stk). In erythroid cells, SFFV gp55 interacts with the EpoR complex and sf-Stk, leading to activation of the kinase and constitutive activation of signal transducing molecules. In this study, we demonstrate that SFFV gp55 can also deregulate the growth of nonerythroid cells when it is coexpressed with sf-Stk. Expression of SFFV gp55 in rodent fibroblasts engineered to express sf-Stk induced their transformation, as demonstrated by focus formation and anchorage-independent growth in vitro. This transformation by SFFV gp55 requires the kinase activity of sf-Stk and the presence of its extracellular domain but not expression of the EpoR or the tyrosine kinase Jak2, which is required for activation of signal transduction pathways through the EpoR. Thus, expression of SFFV gp55 in nonerythroid cells coexpressing sf-Stk results in their uncontrolled growth, demonstrating a previously unrecognized mechanism for retrovirus transformation of rodent fibroblasts and providing insight into SFFV-induced disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223879      PMCID: PMC1266114          DOI: 10.1073/pnas.0506570102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Friend erythroleukemia revisited.

Authors:  P A Ney; A D D'Andrea
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Avian hemangioma retrovirus induces cell proliferation via the envelope (env) gene.

Authors:  A Alian; D Sela-Donenfeld; A Panet; A Eldor
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

3.  Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus.

Authors:  Lisa D Finkelstein; Paul A Ney; Qing-Ping Liu; Robert F Paulson; Pamela H Correll
Journal:  Oncogene       Date:  2002-05-16       Impact factor: 9.867

Review 4.  Deregulation of erythropoiesis by the Friend spleen focus-forming virus.

Authors:  S K Ruscetti
Journal:  Int J Biochem Cell Biol       Date:  1999-10       Impact factor: 5.085

5.  Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation.

Authors:  S K Rai; F M Duh; V Vigdorovich; A Danilkovitch-Miagkova; M I Lerman; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

6.  Direct transformation of rodent fibroblasts by jaagsiekte sheep retrovirus DNA.

Authors:  N Maeda; M Palmarini; C Murgia; H Fan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

7.  The envelope glycoprotein of friend spleen focus-forming virus covalently interacts with and constitutively activates a truncated form of the receptor tyrosine kinase Stk.

Authors:  K Nishigaki; D Thompson; C Hanson; T Yugawa; S Ruscetti
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Ex vivo and in vivo biological effects of a truncated form of the receptor tyrosine kinase stk when activated by interaction with the friend spleen focus-forming virus envelope glycoprotein or by point mutation.

Authors:  Karen Rulli; Takashi Yugawa; Charlotte Hanson; Delores Thompson; Sandra Ruscetti; Kazuo Nishigaki
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  The erythropoietin receptor transmembrane domain mediates complex formation with viral anemic and polycythemic gp55 proteins.

Authors:  Stefan N Constantinescu; Tzvia Keren; William P Russ; Iban Ubarretxena-Belandia; Yaniv Malka; Katharina F Kubatzky; Donald M Engelman; Harvey F Lodish; Yoav I Henis
Journal:  J Biol Chem       Date:  2003-08-20       Impact factor: 5.157

10.  MMTV Env encodes an ITAM responsible for transformation of mammary epithelial cells in three-dimensional culture.

Authors:  Elad Katz; Mohamed H Lareef; John C Rassa; Shannon M Grande; Leslie B King; Jose Russo; Susan R Ross; John G Monroe
Journal:  J Exp Med       Date:  2005-01-31       Impact factor: 14.307

View more
  13 in total

1.  Role of phosphatidylinositol 3-kinase in friend spleen focus-forming virus-induced erythroid disease.

Authors:  Daigo Umehara; Shinya Watanabe; Haruyo Ochi; Yukari Anai; Nursarat Ahmed; Mari Kannagi; Charlotte Hanson; Sandra Ruscetti; Kazuo Nishigaki
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  The tyrosine kinase sf-Stk and its downstream signals are required for maintenance of friend spleen focus-forming virus-induced fibroblast transformation.

Authors:  Tanya M Jelacic; Delores Thompson; Charlotte Hanson; Joan L Cmarik; Kazuo Nishigaki; Sandra Ruscetti
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

3.  Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.

Authors:  Xuemei Liu; Ling Zhao; Yoko S Derose; Yi-Chun Lin; Magdalena Bieniasz; Henok Eyob; Saundra S Buys; Leigh Neumayer; Alana L Welm
Journal:  Genes Cancer       Date:  2011-07

4.  Role of N-terminal sequences of the tyrosine kinase sf-Stk in transformation of rodent fibroblasts by variants of Friend spleen focus-forming virus.

Authors:  Daigo Umehara; Maki Kawamura; Yuka Odahara; Shinya Watanabe; Charlotte Hanson; Sandra Ruscetti; Kazuo Nishigaki
Journal:  Int J Cancer       Date:  2011-12-05       Impact factor: 7.396

5.  The prostate cancer-associated human retrovirus XMRV lacks direct transforming activity but can induce low rates of transformation in cultured cells.

Authors:  Michael J Metzger; Christiana J Holguin; Ramon Mendoza; A Dusty Miller
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

6.  Importance of receptor usage, Fli1 activation, and mouse strain for the stem cell specificity of 10A1 murine leukemia virus leukemogenicity.

Authors:  Michaela Rodenburg; Meike Fischer; Afra Engelmann; Stephanie O Harbers; Marion Ziegler; Jürgen Löhler; Carol Stocking
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Activation of the N-terminally truncated form of the Stk receptor tyrosine kinase Sf-Stk by Friend virus-encoded gp55 is mediated by cysteine residues in the ecotropic domain of gp55 and the extracellular domain of Sf-Stk.

Authors:  Shihan He; Shuang Ni; Shailaja Hegde; Xin Wang; Daniel R Sharda; Avery August; Robert F Paulson; Pamela A Hankey
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

Review 8.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

9.  Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo.

Authors:  Bradley S Barrett; Kejun Guo; Michael S Harper; Sam X Li; Karl J Heilman; Nicholas O Davidson; Mario L Santiago
Journal:  Virology       Date:  2014-10-07       Impact factor: 3.616

10.  Fv1 restriction and retrovirus vaccine immunity in Apobec3-deficient 129P2 mice.

Authors:  Kalani Halemano; Bradley S Barrett; Sam X Li; Michael S Harper; Diana S Smith; Karl J Heilman; Mario L Santiago
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.